ADDRESS-2 is supporting a study to assess the safety of a new “type 1 diabetes vaccine” designed to stop the immune system from attacking insulin-producing beta cells.
ADDRESS-2 is now supporting a study to understand better the effect of the drug Abatacept on the immune system in new-onset type 1 diabetes, and how it might work to preserve beta cells.
ADDRESS-2 is now supporting a major European study aiming to improve the understanding of type 1 diabetes and and pave the way to new therapeutic options to prevent and cure the disease.
ADDRESS-2 is now supporting a study to understand better how much insulin people with type 1 diabetes can make within the first year of diagnosis.
We are now supporting a study looking at what the immune system is doing in people very newly diagnosed with type 1 diabetes.